Forgot your password?

Forgot your username?

database > company
Avanir Pharmaceuticals
Biotech Specialty Pharma
101 Enterprise, Suite 300
Aliso Viejo, CA 92656 USA
phone:(949) 389-6700
fax:(718) 921-8334
Symbol AVNR
Exchange NASDAQ
Founded 0
Employees 63
www.avanir.com
Research Sector Biotech Specialty Pharma
Summary Description
Treatments for CNS disorders and inflammatory diseases.
Management
Stephen G. Austin, Cpa, Independent Director; Keith A. Katkin, Inside Director; Charles A. Mathews, Independent Director; David J. Mazzo, Ph.D., Independent Director; Dennis G. Podlesak, Independent Director
Ownership
Financials Mkt Cap :107


* numbers in thousands
 

Keywords
inflammatory, cold sores, herpes, central nervous disorders, cardiovascularm infectious

Comment | Printable Version | Modify profile |
Updated: Mar. 07, 2011

Description
AVANIR PHARMACEUTICALS is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR'S products and product candidates address therapeutic markets that include central nervous system disorders, cardiovascular disorders, inflammation, and infectious disease.
Products / Services
The company's first commercialized product, abreva?, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Avanir also markets FazaClo?, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments.
Strategy
The company's first commercialized product, abreva?, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.
Status
Zenvia(tm), Avanir's lead product candidate for the treatment of involuntary emotional expression disorder (IEED), is the subject of an approvable letter from the FDA and future development plans for this product candidate are under consideration.


2012-01-31-563